ClinicalTrials.gg
CompletedNCT06745271Updated Mar 18, 2025

A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants

A Phase 1 interventional study of [14C]-tebapivat and [13C2,15N3]-tebapivat in Healthy Participants, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary purpose of this study is to determine the routes, rates of elimination, mass balance of total radioactivity and metabolite profiles following a single oral dose of [14C]-tebapivat. To characterize the PK of tebapivat and [13C2,15N3]-tebapivat and determine the absolute bioavailability following single oral dose of [14C]-tebapivat relative to single intravenous microdose of [13C2,15N3]-tebapivat to healthy male participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, of any race, between 18 and 55 years of age, inclusive.

    a. Males must agree to use .

  2. between 18.0 and 30.0 kilograms per meter square (kg/m2), inclusive, and a body weight between 50 and 100 kilograms (kg), inclusive.
  3. In good health, as determined by no findings from medical history, 12-lead and vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in, and from the physical examination at check-in, as assessed by the investigator or designee.
  4. History of a minimum of 1 bowel movement per day.
  5. Able to comprehend and are willing to sign the form (ICF) and abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator or designee.
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed; cholecystectomy is not allowed).
  4. Positive hepatitis panel and/or positive test. Participants whose results are compatible with prior immunization may be included.
  5. Administration of any vaccine within 30 days prior to dosing.
  6. Use or intend to use any medications/products known to alter drug absorption, metabolism, and excretion (AME) processes, including St. John's wort, within 30 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  7. Use or intend to use any prescription medications/products within 14 days or 5 half-lives (whichever is longer) prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  8. Use or intend to use any slow release medications/products considered to still be active within 14 days or 5 half-lives (whichever is longer) prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  9. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  10. Participation in a clinical study involving administration of an IMP (new chemical entity) in the past 30 days or 5 half-lives of that drug (if known) prior to dosing, whichever is longer.
  11. Have previously completed or withdrawn from this study or any other study investigating tebapivat and have previously received tebapivat.
  12. Participants who have previously been dosed in >1 radiolabeled drug study in the last 12 months. For participants who have previously been dosed in 1 radiolabeled drug study within the last 12 months, the previous radiolabeled dose must be at least 6 months prior to check-in at the clinical research unit (CRU). The total 12 month exposure from this study and a maximum of 1 other previous radiolabeled study must be within the Code of Federal Regulations (CFR) recommended levels considered safe, per United States (US) Title 21 CFR 361.1.
  13. Alcohol consumption of >21 units per week. One unit of alcohol equals 12 ounces (oz) (360 milliliters (mL)) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
  14. Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
  15. History of alcoholism or drug/chemical abuse within 2 years prior to check-in.
  16. Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.
  17. Receipt of blood products within 2 months prior to check-in.
  18. Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or from 6 weeks prior to screening.
  19. Poor peripheral venous access.
  20. Participants with exposure to significant diagnostic or therapeutic radiation (e.g., serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
  21. Participants who, in the opinion of the investigator or designee, should not participate in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-tebapivat and [13C2,15N3]-tebapivat

    Participants will receive a single oral dose of 10 milligrams (mg) \[14C\]-tebapivat containing 200 microcurie \[μCi\] of radiocarbon in a capsule followed by a single intravenous (IV) microdose of 0.1 mg \[13C2,15N3\]-tebapivat on Day 1.

    Drug: [14C]-tebapivat · Drug: [13C2,15N3]-tebapivat

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Radioactive Dose Excreted in Urine Over a Time Interval (feut1-t2) of [14C]-Tebapivat

    Time frame: Up to Day 42

  2. Percentage of Radioactive Dose Excreted in Feces Over a Time Interval (fef t1-t2) of [14C]-Tebapivat

    Time frame: Up to Day 42

  3. Cumulative Percentage of Radioactive Dose Excreted in Urine Over a Time Interval (Cum feut1-t2) of [14C]-Tebapivat

    Time frame: Up to Day 42

  4. Cumulative Percentage of Radioactive Dose Excreted in Feces Over a Time Interval (Cum fef t1-t2) of [14C]-Tebapivat

    Time frame: Up to Day 42

  5. Percentage of Total Radioactivity in Total Excreta (Feces + Urine) (Cum fe) of [14C]-Tebapivat

    Time frame: Up to Day 42

  6. Amount of Drug Excreted in Urine (Aeu) of [14C]-Tebapivat

    Time frame: Up to Day 42

  7. Cumulative Amount of Drug Excreted in Urine (Cum Aeu) of [14C]-Tebapivat

    Time frame: Up to Day 42

  8. Renal Clearance (CLR) of [14C]-Tebapivat

    Time frame: Up to Day 42

  9. Area Under the Concentration-Time Curve (AUC) From Time 0 to 168 Hours Postdose (AUC0-168) in Plasma for [14C]-Tebapivat and [13C2,15N3]-Tebapivat

    Time frame: Up to Day 7

  10. AUC0-168 in Plasma and Whole Blood for Total Radioactivity

    Time frame: Up to Day 7

  11. AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) in Plasma for [14C]-Tebapivat and [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  12. AUC0-t in Plasma and Whole Blood for Total Radioactivity

    Time frame: Up to Day 42

  13. AUC Extrapolated to Infinity (AUC0-inf) in Plasma for [14C]-Tebapivat and [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  14. (AUC0-inf) in Plasma and Whole Blood for Total Radioactivity

    Time frame: Up to Day 42

  15. Maximum Observed Plasma Concentration (Cmax) for [14C]-Tebapivat and [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  16. Cmax in Plasma and Whole Blood for Total Radioactivity

    Time frame: Up to Day 42

  17. Time to Reach Cmax (Tmax) for [14C]-Tebapivat and [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  18. Tmax in Plasma and Whole Blood for Total Radioactivity

    Time frame: Up to Day 42

  19. Terminal Elimination Half-Life (t1/2) in Plasma for [14C]-Tebapivat and [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  20. T1/2 in Plasma and Whole Blood for Total Radioactivity

    Time frame: Up to Day 42

  21. Ratio of AUC0-inf for Tebapivat to AUC0-inf for Total Radioactivity in Plasma

    Time frame: Up to Day 42

  22. Ratio of AUC0-inf for Total Radioactivity in Whole Blood to AUC0-inf for Total Radioactivity in Plasma

    Time frame: Up to Day 42

  23. Total Clearance Following IV Administration (CL) of [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  24. Apparent Volume of Distribution During the Terminal Phase Following IV Administration (Vz) of [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  25. Apparent Volume of Distribution at Steady State Following IV Administration (Vss) of [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  26. Ratio of Dose-Normalized AUC0-inf of Oral Administration of [14C]-Tebapivat Relative to IV Administration of [13C2,15N3]-Tebapivat

    Time frame: Up to Day 21

  27. Quantitation of Major Metabolites of [14C]-Tebapivat in Plasma After Oral Administration

    Quantification of major metabolites of \[14C\]-tebapivat in plasma.

    Time frame: Up to Day 21

  28. Quantitation of Major Metabolites of [14C]-Tebapivat in Excreta After Oral Administration

    Quantification of major metabolites of \[14C\]-tebapivat in excreta.

    Time frame: Up to Day 42

  29. Identification of Chemical Structure of Major Metabolites of [14C]-Tebapivat in Plasma After Oral Administration

    Identification of the chemical structures of major metabolites of \[14C\]-tebapivat in plasma.

    Time frame: Up to Day 21

  30. Identification of Chemical Structure of Major Metabolites of [14C]-Tebapivat in Excreta After Oral Administration

    Identification of the chemical structures of major metabolites of \[14C\]-tebapivat in excreta.

    Time frame: Up to Day 42

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs) by Type, Severity, and Relationship to Study Drug

    Time frame: Up to Day 28

  2. Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Assessments

    Time frame: Baseline up to Day 28

  3. Number of Participants With Clinically Significant Change From Baseline in Abnormal 12-Lead Electrocardiogram (ECG) Parameters

    Time frame: Baseline up to Day 28

  4. Number of Participants With Clinically Significant Change From Baseline in Abnormal Vital Signs Measurements

    Time frame: Baseline up to Day 28

07

Study locations

1 site
  • Taha El-Shahat
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Feb 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
Dec 20, 2024
Primary completionActual
Feb 21, 2025
CompletionActual
Feb 21, 2025
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06745271
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Dec 20, 2024
Primary completion
Feb 21, 2025
Completion
Feb 21, 2025
Last update
Mar 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebapivat

Start the discussion